SCHEMBL4229012

SCHEMBL4229012

CCOc1cc(NC(=O)NC(CC)CC)c(F)cc1Oc1ccc(N)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.50
TAS1R3 Q7RTX0 3/20 0.47
TAS1R1 Q7RTX1 3/20 0.47
POLB P06746 2/20 0.44
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.39
TP53 P04637 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
FPR2 P25090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4234355 0.91 TAS1R3 (0.57) PKMTAS1R3TAS1R1POLBMAPK1
SCHEMBL4226776 0.89 PKM (0.54) PKMTAS1R3TAS1R1POLBNPC1
SCHEMBL4226643 0.86 PKM (0.47) PKMTAS1R3TAS1R1POLBNPC1
SCHEMBL4236309 0.85 TAS1R3 (0.50) PKMTAS1R3TAS1R1POLBKMT2A
SCHEMBL4787232 0.83 EPHX2 (0.48) PKMPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL4236455 0.82 PKM (0.63) PKMTAS1R3TAS1R1POLBNPC1
SCHEMBL4236665 0.82 PKM (0.52) PKMTAS1R3TAS1R1POLBNPC1
SCHEMBL4237834 0.80 TAS1R3 (0.55) PKMTAS1R3TAS1R1POLBRAB9A
SCHEMBL4226773 0.79 PKM (0.52) PKMTAS1R3TAS1R1POLBMAPK1
SCHEMBL4233572 0.78 TAS1R3 (0.55) PKMTAS1R3TAS1R1POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.